Aktienanalyse zu Dr Reddy's Laboratories Ltd (RDY)RDYDr Reddy's Laboratories Ltd

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dr Reddy's Laboratories Ltd is a good buy right now due to its current price of $12.48, which is below its historical trading range of $11.36 to $15.67, indicating potential upside. The RSI is at 57.067, suggesting the stock is neither overbought nor oversold, which is favorable for entry. Additionally, the company recently launched a generic version of Sugammadex in the U.S., which could significantly enhance revenue, as the original product had $1.6 billion in sales. However, the main risk is the forward P/E ratio of 27.027, indicating that the stock may be overvalued compared to its earnings potential.

1 analysts cover RDY: 0 rate it Buy, 0 Hold and 1 Sell.